You are here
Phase 2 Trial Evaluates Safety, Biologic, and Therapeutic Activity of Xcellerated T Cells in Relapsed Multiple Myeloma
"This is our second clinical trial of Xcellerated T Cells in patients with multiple myeloma," said Mark Frohlich, M.D., Medical Director and Vice President of Xcyte Therapies. "In our first trial in patients undergoing high dose chemotherapy followed by peripheral blood stem cell transplantation, we have observed rapid and sustained lymphocyte recovery. In addition, the majority of patients have had clinical responses following the combination treatment of the transplant and Xcellerated T Cells. Based on these results, we are now examining the safety and efficacy of Xcellerated T Cells without additional anti-tumor therapy in patients with relapsed or refractory disease."
Multiple myeloma is one of the most common cancers of the bone marrow. In 2003, the American Cancer Society estimated that there were approximately 14,600 new cases of multiple myeloma, and about 10,900 patients died of the disease in the United States. Multiple myeloma is most often diagnosed in middle-aged and elderly individuals. A variety of standard chemotherapy agents have been used to treat this disease, but few patients experience long-term disease-free survival.
Xcyte Therapies is developing novel therapies that harness the power of the immune system to treat cancer and other serious illnesses. Xcyte derives its therapeutic products from a patient's own T cells, which are cells of the immune system that orchestrate immune responses and can detect and eliminate cancer cells and infected cells in the body. Xcyte uses its patented and proprietary Xcellerate Technology to generate activated T cells, called Xcellerated T Cells, from blood that is collected from the patient. Activated T cells are T cells that have been stimulated to carry out immune functions. The Xcellerate Technology is designed to rapidly activate and expand the number of the patient's T cells outside of the body. These Xcellerated T Cells are then administered to the patient.
Source: Xcyte Therapies, Inc.